The present invention relates to a method for treating Parkinsons disease associated with aggregation of alpha-synuclein. More specifically, regulation of N-methyl-D-aspartate (NMDA) receptors on a cell surface using galectin-1 derived from mesenchymal stem cells brings inhibition of clathrin-mediated endocytosis (CME) of extracellular alpha-synuclein, thereby blocking formation of alpha-synuclein aggregates. Thus, it is possible to treat or prevent disease such as Parkinsons disease induced by alpha-synuclein aggregation.
展开▼
